Aeovian Pharmaceuticals
San Francisco
About Aeovian Pharmaceuticals
Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways, including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $142.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: aeovian.com
- Phone: +1 510-961-1148
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aeovian-pharmaceuticals-10895 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.